Cognition Therapeutics Advances Drug Candidate CT1812 to Phase 3 After Promising Phase 2 Results
Cognition Therapeutics CEO discusses breakthrough in developing oral medications for neurodegenerative disorders. CT1812 shows promising results in phase 2 trial, moving to phase 3. Significant progress in treating critical forms of dementia.
This news highlights significant progress in the development of potential treatments for neurodegenerative disorders, offering hope for patients and their families. It signifies a step forward in addressing critical forms of dementia, potentially improving the quality of life for those affected.
